세계 방사면역측정법(RIA) 시장 규모는 2023년 5억 2,398만 달러, 2030년까지 6억 6,031만 달러에 달할 것으로 예상되며, 2024-2030년의 예측 기간 동안 연평균 3.36%를 나타낼 전망입니다. 방사면역측정법(RIA)에 대한 수요는 주로 암, 감염성 질환 등의 유병률 증가, 전염병 및 전염병의 발병률 증가, 건강에 대한 인식 증가에 의해 주도되고 있습니다. 또한, 이 분야에서 진행 중인 수많은 연구 활동, 의료 서비스 제공업체, 연구자, 업계 진입자의 협력, 전략적 파트너십 등이 2024-2030년의 예측 기간 동안 시장의 전반적인 성장에 기여할 것으로 예상됩니다.
방사성면역측정법(RIA) 시장 역학
국제암연구소(International Agency for Research on Cancer)의 조사에 따르면, 2020년 전 세계적으로 약 1,930만 건의 신규 암이 보고되었습니다.
세계보건기구(WHO) 자료에 따르면 2020년 전 세계적으로 유방암 226만 건, 폐암 221만 건, 대장암 193만 건, 전립선암 141만 건, 위암 109만 건이 보고됐습니다.
암 증가로 인해 조기에 효과적인 진단이 필요하며, 이는 방사성동위원소 분석법(RIA)을 통해 가능합니다. RIA는 대장암, 췌장암 등의 조기 발견에 매우 중요한 것으로 알려져 있습니다.
또한 세계보건기구(WHO)(2022)에 따르면 2020년 전 세계 약 3,770만 명이 인간면역결핍바이러스(HIV)에 감염되었으며, WHO의 2023년 데이터에 따르면 2022년 전 세계적으로 약 1,000만 명이 결핵에 감염된 것으로 추정됩니다. 이 추정치는 결핵의 유병률이 증가 추세에 있으며, 효과적인 진단을 위한 방사면역측정법(RIA)에 대한 수요가 증가할 것임을 보여줍니다.
그러나 방사성 물질의 사용, 첨단 실험 시설의 필요성, 다른 진단 도구 및 방법과 결합된 방사면역측정법(RIA)의 사용과 관련된 제약 등 여러 가지 제약이 전체 방사면역측정법(RIA) 시장의 성장을 억제할 수 있습니다.
라디오임unoassay(RIA) 시장 부문별 분석
라디오イムunoassay(RIA) 시장의 제품 유형에서 분석기는 2023년 큰 매출 점유율을 차지할 것으로 예상됩니다.
이는 전 세계적으로 전염병 및 유행성 질환의 발병률 증가와 간염과 같은 감염성 질환의 높은 발병률에 기인하는 것으로 보입니다.
WHO(2022) 자료에 따르면, 2020년 전 세계적으로 약 2억 4,100만 명이 말라리아에 걸렸다고 합니다.
WHO(2021) 데이터에 따르면 전 세계적으로 매일 약 100만 명이 성병에 감염되고 있습니다. 또한 이 데이터에 따르면 2020년 클라미디아 약 1억 2,900만 건, 매독 7억 1,000만 건, 임질 8,200만 건, 트리코모나스 약 1억 5,600만 건이 존재한 것으로 추산됩니다.
미국 질병통제예방센터(2021)에 따르면, 세계보건기구(WHO) 추산에 따르면 2019년 전 세계적으로 약 2억 9,600만 명이 B형 간염에 걸렸고, 5,800만 명이 C형 간염에 걸렸다고 합니다.
RIA(Radioimmunoassay) 분석기는 시료 내 특정 물질의 농도를 식별하고 검출하는 데 사용되며, 다양한 검사를 수행할 수 있습니다. 이 분석기는 신뢰성이 향상되고 직관적인 인터페이스와 사용하기 쉬운 기능을 갖추고 있습니다.
따라서, 위의 요인으로 인해 분석기 카테고리는 큰 성장을 기록할 것으로 예상되며, 이로 인해 예측 기간 동안 전체 방사면역측정법(RIA) 시장의 성장을 가속할 것으로 예상됩니다.
북미가 전체 방사성동위원소 분석(RIA) 시장을 독점할 것으로 예상됩니다.
미국 질병예방통제센터(2022)에 따르면, 2019년 미국에서 13세 이상 약 118만 9,700명이 HIV에 감염된 것으로 추정됩니다. 미국 질병통제예방센터(CDC)(2022)에 따르면 2019년에 약 175만 2,735명의 신규 암 환자가 보고되었습니다.
이 보고서는 세계 방사선 면역 분석(RIA) 시장에 대해 조사 분석했으며, 시장 규모와 예측, 촉진요인 및 과제, 기업 및 제품 프로파일 등의 정보를 전해드립니다.
The Radioimmunoassay (RIA) Market By Product Type (Analyzers And Reagents & Kits), Application (Research And Clinical Diagnostics), End-User (Hospitals, Clinical Diagnostic Laboratories, Pharmaceutical Industries, And Others) and geography is expected to grow at a steady CAGR forecast till 2030 owing to increasing number of people with infectious diseases and increasing research and development activities
The global Radioimmunoassay (RIA) market was valued at USD 523.98 million in 2023, growing at a CAGR of 3.36% during the forecast period from 2024 to 2030 to reach USD 660.31 million by 2030. The demand for radioimmunoassay is primarily being boosted by the growing prevalence of cancer, infectious diseases, and others, rising incidences of epidemics and pandemics coupled with growing awareness of health. Furthermore, the radioimmunoassay market is anticipated to grow on account of a large number of ongoing research activities in this field, collaborations between healthcare providers, researchers, and industry players, and strategic partnerships among others are going to contribute to the overall growth of the radioimmunoassay market during the forecast period from 2024-2030.
Radioimmunoassay (RIA) Market Dynamics:
The study conducted by the International Agency for Research on Cancer mentioned that worldwide, an estimated 19.3 million new cancer cases were reported in 2020.
According to the data cited by the World Health Organization 2022, worldwide around 2.26 million cases of breast, 2.21 million cases of lung, 1.93 million cases of colon and rectum, 1.41 million cases of prostate, and 1.09 million cases of stomach cancer were reported in 2020.
The increasing burden of cancer necessitates its early and effective diagnosis which can be possible via the usage of radioimmunoassay. Radioimmunoassay is found to be crucial for detecting the early stages of cancer of the colon and pancreas among others.
Also, according to the World Health Organization (WHO) 2022, globally around 37.7 million people suffered from human immunodeficiency virus (HIV) in the year 2020. As per the 2023 data provided by WHO, globally around 10 million people suffered from tuberculosis in 2022. The estimates suggest that the prevalence of infectious diseases is on the rise and will increase the demand for radioimmunoassay for its effective diagnosis.
However, several limitations such as the use of radioactive substances, the need for advanced lab facilities, and others associated with the use of radioimmunoassay coupled with other diagnostic tools and methods may restrict the growth of the overall radioimmunoassay market.
Radioimmunoassay (RIA) Market Segment Analysis:
Radioimmunoassay Market by Product Type (Analyzers and Reagents & Kits), Application (Research and Clinical Diagnostics), End-User (Hospitals, Clinical Diagnostic Laboratories, Pharmaceutical Industries, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)
In the product type of the radioimmunoassay market, the analyzers, category is expected to amass a significant revenue share in the year 2023.
This can be ascribed to the high incidence of infectious diseases, including hepatitis, and others along with rising incidences of epidemics and pandemics across the globe.
As per the data provided by the WHO 2022, globally around 241 million people suffered from malaria in 2020.
The WHO 2021 data mentioned that, worldwide around 1 million people acquire STDs every day. Also, as per the same source, it was estimated that there were around 129 million cases of chlamydia, 7.1 million cases of syphilis, 82 million cases of gonorrhea, and around 156 million cases of trichomoniasis recorded in the year 2020.
As per Centers for Disease Control and Prevention 2021 based on WHO estimates, in 2019 about 296 million people worldwide were living with hepatitis B, and 58 million people worldwide had hepatitis C.
Radioimmunoassay analyzers can be used to identify and detect the concentration of specific substances in a sample and can perform a variety of tests. The analyzers offer improved reliability, have intuitive interfaces and easy-to-use features.
Therefore, owing to the above-mentioned factors, the analyzers category is expected to register significant growth, thereby driving the growth of the overall radioimmunoassay market during the forecast period.
North America is expected to dominate the overall Radioimmunoassay (RIA) Market:
Among all the regions, North America is estimated to account for the largest share of the Radioimmunoassay market in the year 2023. This can be ascribed to the presence of a large patient pool associated with Sexually transmitted diseases (STSs), cancer, and others, a highly potent market in terms of product development and launches, and the local presence of key market players among other factors in the region.
According to the Centers for Disease Control and Prevention 2022, it was estimated that around 1,189,700 people aged 13 and above had HIV in the US in 2019. As per the Centers for Disease Control and Prevention (CDC) (2022), around 1,752,735 new cancer cases were reported in 2019.
As per the American Thyroid Association 2019, around 20 million people in America have some form of thyroid disease, and an estimated 12 percent or more of American people will develop thyroid disease during their lifetime.
Moreover, as per the US Department of Health and Human Services (HHS) press release in the year 2021, the US government had invested USD 650 million in rapid diagnostic testing in the latest action to increase access to tests.
Thus, the above-mentioned factors are likely to propel the growth of the Radioimmunoassay market in the region during the forecast period from 2024-2030.
Radioimmunoassay (RIA) Market Key Players:
Some of the key market players operating in the Radioimmunoassay market include DIAsource, MP BIOMEDICALS, Merck KGaA, Tecan Trading AG, Svar Life Science, Institute of Isotopes Co. Ltd., PerkinElmer Inc., Danaher Corporation, and Others.
Key Takeaways from the Radioimmunoassay (RIA) Market Report Study
Target Audience who can be benefited from this Radioimmunoassay (RIA) Market Report Study
Frequently Asked Questions for the Radioimmunoassay (RIA) Market:
Radioimmunoassay is for determining antibody levels by introducing an antigen labeled with a radioisotope and measuring the subsequent radioactivity of the antibody component.
The global Radioimmunoassay (RIA) market was valued at USD 523.98 million in 2023, growing at a CAGR of 3.36% during the forecast period from 2024 to 2030 to reach USD 660.31 million by 2030.
The demand for radioimmunoassay is primarily being boosted by the growing prevalence of cancer, infectious diseases, and others, rising incidences of epidemics and pandemics coupled with growing health awareness. Furthermore, the radioimmunoassay market is anticipated to grow on account of a large number of ongoing research activities in this field, collaborations between healthcare providers, researchers, and industry players, and strategic partnerships among others are going to contribute to the overall growth of the radioimmunoassay market during the forecast period from 2024-2030.
Some of the key market players operating in the radioimmunoassay market include DIAsource, MP BIOMEDICALS, Merck KGaA, Tecan Trading AG, Svar Life Science, Institute of Isotopes Co. Ltd., PerkinElmer Inc., Danaher Corporation, and Others.
North America is expected to dominate the overall radioimmunoassay market during the forecast period from 2024-2030. Owing to the significance of key growth factors such as the presence of a large patient pool associated with Sexually transmitted diseases (STSs), cancer, and others, a highly potent market in terms of product development and launches, and the local presence of key market players among other factors in the region.